Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 902

Sort by

Sort Order Select

Journal Articles

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Pierre Stephan, Roberta Di Blasi, Louise Roulin, Jean Galtier, Julien Calvani, Véronique Meignin, Marie Donzel, Alexandra Traverse-Glehen, Elsa Poullot, Marie Parrens, Vivien Dupont, Alexandra Marquet, Steven Le Gouill, Roch Houot, Francois-Xavier Gros, François Lemonnier, Emmanuel Bachy, Catherine Thieblemont, Pierre Sesques

Blood Adv (2025) 9 (18): 4693–4704.

https://doi.org/10.1182/bloodadvances.2025015834

Published: 2025

Includes: Supplemental data

Journal Articles

Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma

Xian G. Zhang, Lin Wang, Junfang Yang, Xiaona N. Hu, Hui Wang, Lina N. Zhang, Xiaoge Zhou, Ying Liu, Qinglong Wang, Peihua H. Lu

Blood Adv (2025) 9 (18): 4543–4552.

https://doi.org/10.1182/bloodadvances.2025016322

Published: 2025

Includes: Supplemental data

Journal Articles

Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study

John C. Panetta, Aimee C. Talleur, Swati Naik, Stephen Gottschalk, Markos Leggas

Blood Adv (2025) 9 (18): 4676–4682.

https://doi.org/10.1182/bloodadvances.2025015928

Published: 2025

Includes: Supplemental data

Journal Articles

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma

Fausto Alfredo Rios-Olais, Talal Hilal

Blood Adv (2025) 9 (18): 4673–4675.

https://doi.org/10.1182/bloodadvances.2025016176

Published: 2025

Includes: Supplemental data

Journal Articles

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Taku Kikuchi, Ukyo Kondo, Shotaro Sugita, Miyu Watanabe, Chiaki Matsumoto, Moe Nomura-Yogo, Kodai Kunisada, Haruka Sawada, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Osamu Hosoya, Tadao Ishida, Nobuhiro Tsukada

Blood Adv (2025) 9 (18): 4716–4719.

https://doi.org/10.1182/bloodadvances.2025017174

Published: 2025

Includes: Supplemental data

Journal Articles

Do not forget vaccinations in patients on Ig replacement

Sigrun Einarsdottir, Silvia Escribano Serrat, Marina Gomez-Llobell, Malin L Hultcrantz, Mini Kamboj, Miguel-Angel Perales, Roni Shouval, Zainab Shahid, Per Ljungman

Blood Adv bloodadvances.2025018127.

https://doi.org/10.1182/bloodadvances.2025018127

Published: 2025

Journal Articles

mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow

Taylor Fulton-Ward, Nancy Gudgeon, Isaac Thirlwell, Emma Louise Bishop, Bryan Marzullo, Hannah Victoria Giles, Dr, Graham McIlroy, Paul Ferguson, Bhuvan Kishore, Kate Rogers, Nuri Nuri Alfasi, Timothy Wong, Satnam Aytain, Daniel A. Tennant, Guy Pratt, Sarah Dimeloe

Blood Adv bloodadvances.2025016439.

https://doi.org/10.1182/bloodadvances.2025016439

Published: 2025

Includes: Supplemental data

Journal Articles

“Optimizing” HLH diagnoses in patients with lymphoma

Joseph M. Rocco, William T. Johnson

Blood Adv (2025) 9 (17): 4513–4514.

https://doi.org/10.1182/bloodadvances.2025017104

Published: 2025

Journal Articles

The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma

Blood Adv (2025) 9 (17): 4515–4525.

https://doi.org/10.1182/bloodadvances.2024014005

Published: 2025

Includes: Supplemental data

Journal Articles

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

Rakesh Awasthi, Stephan A. Grupp, Edward R. Waldron, Gregory A. Yanik, Constantine S. Tam, Susana Rives, Joseph P. McGuirk, Michael A. Pulsipher, Ulrich Jaeger, Gary D. Myers, Peter Borchmann, Stephen J. Schuster, Heather E. Stefanski, Michael R. Bishop, Abhijit Chakraborty, Aisha Masood, André Baruchel, Edmund K. Waller

Blood Adv (2025) 9 (17): 4405–4414.

https://doi.org/10.1182/bloodadvances.2024014995

Published: 2025

Includes: Supplemental data

Journal Articles

Harnessing Viral-Specific T Cells: Expanding Therapeutic Strategies Across Diverse Populations

Navid Djassemi, Benjamin Hanisch, Cecilia Motta, Naseem Maghzian, Anant Vatsayan, Jessica R Durkee-Shock, Michael D. Keller

Blood Adv bloodadvances.2024013727.

https://doi.org/10.1182/bloodadvances.2024013727

Published: 2025

Includes: Supplemental data

Journal Articles

Peripheral neuropathy and BTKis in Waldenström: a response?

Chiara Briani, Bruno Ferrero, Alessandro Salvalaggio, Simone Ragaini, Enrico Amaducci, Irene Dogliotti, Andrea Visentin, Simone Ferrero

Blood Adv (2025) 9 (16): 4319–4320.

https://doi.org/10.1182/bloodadvances.2025016734

Published: 2025

Journal Articles

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

Blood Adv bloodadvances.2025016778.

https://doi.org/10.1182/bloodadvances.2025016778

Published: 2025

Includes: Supplemental data

Journal Articles

Avoid burning bridges before CAR-T therapy in myeloma

Swetha Reddi, Rahul Banerjee

Blood Adv (2025) 9 (16): 4232–4234.

https://doi.org/10.1182/bloodadvances.2025016774

Published: 2025

Journal Articles

IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia

Lijun Hui, Jing Xiao, Zhiling Zhao, Juan Zhang, Huiwen Luan, Jiashen Zhang, Yuxiao Sun, Xianhui Meng, Hongying Wang, Chunling Li, Fangmin Li, Shuhao Ji, Shuping Wei, Fang Li, Hong Yu, Chengyun Zheng, Yang Jiang, Yaopeng Wang, Zunling Li

Blood Adv (2025) 9 (16): 4217–4231.

https://doi.org/10.1182/bloodadvances.2025016432

Published: 2025

Includes: Supplemental data

Journal Articles

A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model

Dorottya Laczko, Patricia Y. Tsao, Ruth-Anne Pai, Joseph Zinski, Michael V Gonzalez, Melanie Mumau, Tobias D Raabe, Hiromi Muramatsu, Norbert Pardi, Taku Kambayashi, David C. Fajgenbaum

Blood Adv bloodadvances.2025016749.

https://doi.org/10.1182/bloodadvances.2025016749

Published: 2025

Includes: Supplemental data

Journal Articles

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Jessica S. Little, Angelica Medina Pena, E. Bridget Kim, Andrew J. Yee, Omar Nadeem, Shonali Midha, Adam S. Sperling, Nikhil C. Munshi, Noopur Raje, Matthew J. Frigault, Diana D. Cirstea, Sarah P. Hammond

Blood Adv (2025) 9 (16): 4190–4194.

https://doi.org/10.1182/bloodadvances.2025016748

Published: 2025

Includes: Supplemental data

Journal Articles

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

Blood Adv (2025) 9 (16): 4151–4166.

https://doi.org/10.1182/bloodadvances.2024015732

Published: 2025

Includes: Supplemental data

Journal Articles

Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study

Blood Adv (2025) 9 (16): 4126–4135.

https://doi.org/10.1182/bloodadvances.2025016158

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Blood Adv (2025) 9 (16): 4081–4089.

https://doi.org/10.1182/bloodadvances.2024015779

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

TRANSCAR: real-world outcomes of CD19 CAR T-cell therapy in relapsed/refractory transformed indolent lymphomas

Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma

Age-adjusted dosing of fludarabine for lymphodepletion in CAR T-cell therapy: a clinical trial simulation study

Estimation of benefit to bispecific antibodies in US patients with lymphoma and multiple myeloma

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Do not forget vaccinations in patients on Ig replacement

mTOR activity and metabolic reprogramming of CD8+ T cells is impaired under hypoxia and within the multiple myeloma bone marrow

“Optimizing” HLH diagnoses in patients with lymphoma

The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma

Evaluation of in vivo CAR transgene levels in tisagenlecleucel-treated patients with relapsed/refractory B-ALL and DLBCL

Harnessing Viral-Specific T Cells: Expanding Therapeutic Strategies Across Diverse Populations

Peripheral neuropathy and BTKis in Waldenström: a response?

Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma

Avoid burning bridges before CAR-T therapy in myeloma

IGSF9-targeted therapy inhibits the progression of acute myeloid leukemia

A patient-derived CABIN1 mutation recapitulates features of idiopathic multicentric Castleman disease in a mouse model

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma

Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study

Outcomes of brexucabtagene autoleucel in patients with relapsed/refractory acute lymphoblastic leukemia with CNS involvement

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only